Argen X SE

argenx is a global immunology company focused on developing and commercializing antibody-based medicines for severe autoimmune diseases. Its flagship product, VYVGART (efgartigimod), is the first-in-class neonatal Fc receptor (FcRn) blocker approved for generalized myasthenia gravis (gMG) across all serotypes, chronic inflammatory demyelinating polyneuropathy (CIDP), and primary immune thrombocytopenia (ITP) in Japan. The company operates under a 'Vision 2030' strategy targeting 50,000 patients on treatment, 10 labeled indications, and five late-stage pipeline candidates by 2030. Its pipeline includes empasiprubart (anti-C2 complement inhibitor) in registrational studies for multifocal motor neuropathy and CIDP, adimanebart (MuSK agonist) in Phase 2 for spinal muscular atrophy, and multiple earlier-stage candidates spanning neurology, rheumatology, nephrology, and dermatology. argenx partners with academic researchers through its Immunology Innovation Program and collaborates with Halozyme for subcutaneous delivery technology and with Lonza and Fujifilm for commercial manufacturing. The company is listed on both Euronext Brussels and Nasdaq under the symbol ARGX. Updated Jul 23, 2026